Pluristem Therapeutics, Inc.
) recently announced that the U.S. National Institute of Allergy
and Infectious Diseases (NIAID) will initiate a
mechanism-of-action study to evaluate Pluristem's PLacental
eXpanded RAD (PLX-RAD) cells for the treatment of acute radiation
The study is expected to start later this month. NIAID aims to
evaluate the impact of PLX-RAD cells on body weight, blood count
parameters, cytokine concentrations and bone marrow at various
intervals following the administration of PLX-RAD cells in
NIAID expects to expand the scope of its PLX-RAD research if
the data from this study on irradiated animals' hematological
systems turns out to be positive.
Meanwhile, Pluristem is also evaluating PLX-RAD cells in the
treatment of bone marrow failure following radio- or
chemotherapy. The study is currently in preclinical stages and
Pluristem hopes to benefit from the data from the NIAID
Pluristem develops and manufactures cell therapy products in
collaboration with companies like
) or through research and clinical institutions.
The cells from placenta are derived using the company's
proprietary PluriX therapy and are known as PLacental eXpanded
cells. Pluristem's first candidate in development, PLX-PAD, is
intended to treat peripheral artery disease (PAD).
We note that Pluristem intends to develop and produce cell
therapy products for the treatment of multiple disorders using
several methods of administration.
Last month, Pluristem released positive top-line results from
a phase I/II trial evaluating the safety and efficacy of PLX-PAD
cells in the treatment of muscle injury. The study met both the
primary and secondary endpoints. The results from the trial
showed that PLX-PAD cells were safe and statistical significance
was reached for the primary efficacy endpoint.
The results indicated that PLX cells might be efficacious in
the treatment of orthopedic injuries including muscles and
We are encouraged by Pluristem's efforts to evaluate the
efficacy of PLX-PAD cells for various indications. Pluristem
currently carries a Zacks Rank #3 (Hold). Some better-ranked
stocks in the same sector include
Biogen Idec Inc.
). Both carry a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
PLURISTEM THERA (PSTI): Free Stock Analysis
UTD THERAPEUTIC (UTHR): Free Stock Analysis
To read this article on Zacks.com click here.